SCHEMBL10000735

SCHEMBL10000735

CC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.83
KDR P35968 7/20 0.83
RET P07949 3/20 0.83
BRAF P15056 3/20 0.83
GSK3B P49841 2/20 0.83
RIPK2 O43353 2/20 0.83
ABCB11 O95342 2/20 0.83
ABL1 P00519 2/20 0.83
HTR1A P08908 2/20 0.83
PDGFRB P09619 2/20 0.83
ADORA3 P0DMS8 2/20 0.83
KIT P10721 2/20 0.83
FGFR1 P11362 2/20 0.83
PDGFRA P16234 2/20 0.83
FLT1 P17948 2/20 0.83
MAOA P21397 2/20 0.83
EPHA1 P21709 2/20 0.83
TBXA2R P21731 2/20 0.83
EPHA2 P29317 2/20 0.83
TTK P33981 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407209 0.92 RAF1 (0.80) RAF1KDRRETBRAFGSK3B
SCHEMBL3408499 0.92 RAF1 (0.83) RAF1KDRRETBRAFGSK3B
SCHEMBL28948534 0.92 RAF1 (0.83) RAF1KDRRETBRAFGSK3B
SCHEMBL29793192 0.92 RAF1 (0.83) RAF1KDRRETBRAFGSK3B
Sorafenib SCHEMBL29349634 0.91 RAF1 (1.00) RAF1KDRRETBRAFGSK3B
SCHEMBL26158852 0.91 RAF1 (0.79) RAF1KDRRETBRAFGSK3B
Sorafenib SCHEMBL8218 0.91 RAF1 (1.00) RAF1KDRRETBRAFGSK3B
Sorafenib SCHEMBL14739751 0.91 RAF1 (1.00) RAF1KDRRETBRAFGSK3B
SCHEMBL29918250 0.91 RAF1 (1.00) RAF1KDRRETBRAFGSK3B
SCHEMBL548133 0.91 RAF1 (1.00) RAF1KDRRETBRAFGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
EP-4122925-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME Medshine Discovery Inc. (CN) 2023-01-25 EP disclosed
US-20220193242-A1 IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-23 US disclosed
US-10787443-B2 RAF-degrading conjugate compounds ZAMBONI CHEM SOLUTIONS INC. (CA) 2020-09-29 US disclosed
WO-2020163594-A1 IMMUNOPHILIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-08-13 WO disclosed
WO-2020163598-A1 IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-08-13 WO disclosed
US-20190183881-A1 USE OF CDK8 INHIBITORS TO TREAT DISEASES OF INFLAMMATION AND AUTOIMMUNITY THE BROAD INSTITUTE, INC. 2019-06-20 US disclosed
US-9902709-B2 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) 2018-02-27 US disclosed
US-9809603-B1 Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same DEUTERX, LLC (US) 2017-11-07 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
US-20120108641-A1 ANTITUMOR COMBINATION INCLUDING AVE8062 AND SORAFENIB SANOFI (FR) 2012-05-03 US disclosed
US-20120009150-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS WEBER OLAF (DE) 2012-01-12 US disclosed
US-20110263657-A1 DIARYL UREAS FOR TREATING HEART FAILURE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-27 US disclosed
US-20110158942-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS WEBER OLAF 2011-06-30 US disclosed
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY DUMAS JACQUES 2011-01-20 US disclosed
US-7838541-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE, LLC (US) 2010-11-23 US disclosed
US-20090306020-A1 Combination therapy comprising diaryl ureas for treating diseases BAYER HEALTHCARE AG (DE) 2009-12-10 US disclosed
US-20090227637-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-09-10 US disclosed
US-20090176791-A1 Diaryl Ureas for Treating Pulmonary Hypertension BAYER HEALTHCARE AG (DE) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193242-A1 IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF CD74, CD2BP2, SERPINB1 RAF1 3758/4885KDR 3287/4885RET 4465/4885
US-20090306020-A1 Combination therapy comprising diaryl ureas for treating diseases CDK6, UBA6, CHUK RAF1 845/4885KDR 1464/4885RET 300/4885
US-20120009150-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS UBA6, MCM6, UBQLN1 RAF1 4258/4885KDR 3530/4885RET 2738/4885
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME PSMA6, PSMC1, PSMA1 RAF1 1691/4885KDR 3355/4885RET 2858/4885
US-20090176791-A1 Diaryl Ureas for Treating Pulmonary Hypertension UBA6, UBQLN1, UTS2R RAF1 3995/4885KDR 2840/4885RET 3652/4885
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR RAF1 867/4885KDR 3/4885RET 499/4885
US-20190183881-A1 USE OF CDK8 INHIBITORS TO TREAT DISEASES OF INFLAMMATION AND AUTOIMMUNITY CDK8, CDK9, CDK6 RAF1 525/4885KDR 3330/4885RET 2763/4885
US-20120108641-A1 ANTITUMOR COMBINATION INCLUDING AVE8062 AND SORAFENIB TP53, AURKB, BRAF RAF1 65/4885KDR 12/4885RET 219/4885
US-20090227637-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS UBA6, MCM6, UBQLN1 RAF1 4258/4885KDR 3530/4885RET 2738/4885
US-20110263657-A1 DIARYL UREAS FOR TREATING HEART FAILURE UBA6, UBQLN1, UHRF1 RAF1 3510/4885KDR 4519/4885RET 4368/4885
US-20110158942-A1 DIARYL UREAS FOR TREATING VIRUS INFECTIONS UBA6, MCM6, UBQLN1 RAF1 4258/4885KDR 3530/4885RET 2738/4885
US-10787443-B2 RAF-degrading conjugate compounds BRAF, RAF1, ARAF RAF1 2/4885KDR 716/4885RET 30/4885
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF RAF1 2/4885KDR 567/4885RET 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.